Skip to main content
Fig. 3 | Biomarker Research

Fig. 3

From: Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma

Fig. 3

Progression free survival (PFS) and overall survival (OS) by NLR. A) Median PFS was 5.6 mo in the <mNLR group (n = 55) vs 5.8 mo in the >mNLR group (n = 55) (HR 0.97, p = 0.90). B) Median OS was NR in the <mNLR group (n = 55) vs 31.8 mo in the >mNLR group (n = 55) (HR 0.42, p = 0.02). C) PFS by NLR quartiles: Q1 (n = 27) HR 0.74, p = 0.32; Q2 (n = 28) HR 0.91, p = 0.76; Q3 (n = 27) HR 0.72, p = 0.27); Q4 (n = 28) reference. D) OS by NLR quartiles: Q1 (n = 27) HR 0.24, p < 0.01; Q2 (n = 28) HR 0.31, p = 0.02; Q3 (n = 27) HR 0.38, p = 0.02; Q4 (n = 28) reference. Q1 (1st quartile), Q2 (2nd quartile), Q3 (3rd quartile), Q4 (4th quartile)

Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us